Anaplastic lymphoma kinase

Anaplastic lymphoma kinase (ALL) is a protein that encodes a gene of the same name. Thus the term can refer to one or the other. As a protein it is found on the surface of cells, where it acts as a signal receptor (a receptor tyrosine kinase), meaning that it is an important regulator of many processes occurring within the cell.

Lymphoma Treatment Center

Insurance Accepted.
Innovative Lymphoma Treatments.
Call 415-343-6162 Today

[UPDATE: "anaplastic lymphoma kinase" is technically no longer in use as the name of the gene; it has been replaced by "anaplastic lymphoma receptor tyrosine kinase".]

While the ALK gene plays an important part in the life of the healthy cell, the gene has been implicated as an oncogene—cancer-causing—when it has been found to be amplified, rearranged, or mutated. Anaplastic lymphoma kinase is also one of the few tyrosine kinases that has been shown to have a role in the pathogenesis (medical terminology meaning the development of a disease) of some lymphomas.

Anaplastic lymphoma kinase in ALCL

Typically, cells express the ALK protein on their surfaces only in cells that are part of the development and maturity of the brain and central nervous system. Normal lymphoid cells, in persons of any age, do not express ALK.

The same is not true for some abnormal lymphoid cells. In fact, ALK expression can be found in over 60 percent of cases of the non-Hodgkin's lymphoma T-cell subtype anaplastic large cell lymphoma (ALCL), an extremely uncommon lymphoma, amounting to about 3 percent of all adult lymphomas. ALCL ALK+ (ALK positive) means that the disease is expressing the ALK protein on the surface of its cells. ALCL ALK- (ALK negative) means that the disease is not expressing the ALK protein. Whereas these two non-Hodgkin's lymphoma subtypes used to be considered two versions of the same disease, recent studies have shown that in fact they are fully separate disease entities with different treatment approaches and differing prognoses.

In fact, the prognosis differs drastically; ALK+ disease enjoys a very good prognosis when treated with CHOP chemotherapy—as many as 80 percent of all patients can look forward to a successful treatment course and a very long disease-free survival. On the other hand, as many as 70 percent of patients with ALK- disease are expected to relapse within five years of treatment.

Anaplastic lymphoma kinase in other cancers

The ALK is not only implicated in anaplastic large cell lymphoma. Recently it has been found to be responsible for a small percentage of neuroblastomas, a childhood form of brain cancer, an even smaller percentage of non small cell lung cancers, and some inflammatory myofibroblastic tumors.

Sources

Lymphoma Treatment Center

Insurance Accepted.
Innovative Lymphoma Treatments.
Call 415-343-6162 Today

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...